Evidence map›Paper›PMID 38605423›Full record

ArticleJournal of experimental & clinical cancer research : CR2024

HERC5 downregulation in non-small cell lung cancer is associated with altered energy metabolism and metastasis.

Svenja Schneegans, Jana Löptien, Angelika Mojzisch, Desirée Loreth, Oliver Kretz, Christoph Raschdorf, Annkathrin Hanssen, Antonia Gocke, Bente Siebels, Karthikeyan Gunasekaran and 10 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Translational lung cancer research · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Metabolic adaptations of brain metastasis.Nature reviews. Cancer · 2025
    Review
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 2 countries.

Svenja Schneegans *Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Jana Löptien *Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Angelika MojzischDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Desirée LorethDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Oliver KretzIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christoph RaschdorfDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Annkathrin HanssenDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Antonia GockeSection Mass Spectrometry and Proteomics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Bente SiebelsSection Mass Spectrometry and Proteomics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Karthikeyan GunasekaranDepartment of Biochemistry and Molecular Cell Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Yi DingDepartment of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Leticia Oliveira-FerrerDepartment of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Laura BrylkaDepartment of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Thorsten SchinkeDepartment of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Hartmut SchlüterSection Mass Spectrometry and Proteomics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ilkka PaateroTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Hannah VoßSection Mass Spectrometry and Proteomics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Stefan WernerDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Klaus PantelDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Harriet WikmanDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. h.wikman@uke.de.ORCID http://orcid.org/0000-0001-6862-0888
Universität Hamburg · DEÅbo Akademi University · FI

Funding

Wilhelm Sander-Stiftung 2017.142.1
6 · The paper itself

Abstract

backgroundMetastasis is the leading cause of cancer-related death in non-small cell lung cancer (NSCLC) patients. We previously showed that low HERC5 expression predicts early tumor dissemination and a dismal prognosis in NSCLC patients. Here, we performed functional studies to unravel the mechanism underlying the "metastasis-suppressor" effect of HERC5, with a focus on mitochondrial metabolism pathways.

methodsWe assessed cell proliferation, colony formation potential, anchorage-independent growth, migration, and wound healing in NSCLC cell line models with HERC5 overexpression (OE) or knockout (KO). To study early tumor cell dissemination, we used these cell line models in zebrafish experiments and performed intracardial injections in nude mice. Mass spectrometry (MS) was used to analyze protein changes in whole-cell extracts. Furthermore, electron microscopy (EM) imaging, cellular respiration, glycolytic activity, and lactate production were used to investigate the relationships with mitochondrial energy metabolism pathways.

resultsUsing different in vitro NSCLC cell line models, we showed that NSCLC cells with low HERC5 expression had increased malignant and invasive properties. Furthermore, two different in vivo models in zebrafish and a xenograft mouse model showed increased dissemination and metastasis formation (in particular in the brain). Functional enrichment clustering of MS data revealed an increase in mitochondrial proteins in vitro when HERC5 levels were high. Loss of HERC5 leads to an increased Warburg effect, leading to improved adaptation and survival under prolonged inhibition of oxidative phosphorylation.

conclusionsTaken together, these results indicate that low HERC5 expression increases the metastatic potential of NSCLC in vitro and in vivo. Furthermore, HERC5-induced proteomic changes influence mitochondrial pathways, ultimately leading to alterations in energy metabolism and demonstrating its role as a new potential metastasis suppressor gene.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAnimalsCell Line, TumorCell MovementCell ProliferationDown-RegulationEnergy MetabolismHumansIntracellular Signaling Peptides and ProteinsMiceMice, NudeProteomicsZebrafishHERC5 protein, humanIntracellular Signaling Peptides and ProteinsCancer metabolismDTCHERC5MetastasisMitochondriaNSCLCOXPHOSWarburg effect

Identifiers

PMID38605423
PMCPMC11008035
OpenAlexW4394724822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.